flumazenil has been researched along with Anxiety Neuroses in 20 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the possibility that abnormal regulation of benzodiazepine receptor (BZR) function may relate to the pathophysiology of anxiety disorders, two doses of the BZR antagonist flumazenil (Ro 15-1788) and placebo were administered to panic disorder patients in a double-blind, randomized, crossover design." | 5.07 | Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. ( Charney, DS; Heninger, GR; Krystal, JH; Silver, JM; Woods, SW, 1991) |
| "Self-reported withdrawal symptoms and psychological state and anxiety sequelae were collected at baseline and then at intervals to 5 days following initiation of subcutaneous flumazenil infusion." | 2.78 | Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. ( Bennett, K; Hood, S; Hulse, G; Morris, N; Norman, A; O'Neil, G, 2013) |
| "Flumazenil is a relatively pure benzodiazepine/GABAA antagonist with limited intrinsic activity." | 2.68 | Effects of the benzodiazepine antagonist flumazenil in PTSD. ( Bremner, JD; Charney, DS; Heninger, GR; Krystal, JH; Nagy, LM; Nicolaou, AL; Randall, PK, 1995) |
| "The aim of this study is to determine whether long-term use (5-20 years) of therapeutic doses of diazepam (5-20 mg/day) in anxious patients (n = 28) is associated with tolerance to its psychomotor and cognitive effects." | 2.67 | Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users. ( Bernik, MA; Gorenstein, C; Pompéia, S, 1994) |
| " The limitations in their use both as choice of therapy and with respect to conservative dosage and duration of use are highlighted." | 2.47 | Benzodiazepines revisited--will we ever learn? ( Lader, M, 2011) |
| "FG 7142 anorexia was blocked by the benzodiazepine receptor antagonist flumazenil in a 2:1 molar ratio (n=17 rats)." | 1.34 | FG 7142 specifically reduces meal size and the rate and regularity of sustained feeding in female rats: evidence that benzodiazepine inverse agonists reduce food palatability. ( Cottone, P; Sabino, V; Steardo, L; Zorrilla, EP, 2007) |
| "The purpose of this study is visual evaluation of the distribution of I-123 iomazenil in the brains of patients with various types of mental disorder and to examine whether chronic administration of a clinical dose of benzodiazepine (BZ) affects the binding of I-123 iomazenil to BZ receptors (BZR)." | 1.30 | I-123 iomazenil SPECT in patients with mental disorders. ( Nakabeppu, Y; Nakajo, M; Naruo, T; Nozoe, S; Obo, Y; Takigawa, M; Tanaka, H; Tani, A; Tsuchimochi, S, 1997) |
| " A few subjects taking higher chronic benzodiazepine dosages experienced breakthrough anxiety or withdrawal symptoms, which were well managed by dosing flumazenil immediately before the anesthetic agent and by immediate posttreatment benzodiazepine administration." | 1.30 | The use of flumazenil in the anxious and benzodiazepine-dependent ECT patient. ( Krystal, AD; Lindahl, V; Moore, S; Steffens, DC; Watts, BV; Weiner, RD, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (65.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallo, AT | 1 |
| Hulse, GK | 1 |
| dos Reis, LM | 1 |
| Canto-de-Souza, A | 1 |
| Lader, M | 1 |
| Hulse, G | 1 |
| O'Neil, G | 1 |
| Morris, N | 1 |
| Bennett, K | 1 |
| Norman, A | 1 |
| Hood, S | 1 |
| Kosel, M | 1 |
| Rudolph, U | 1 |
| Wielepp, P | 1 |
| Luginbühl, M | 1 |
| Schmitt, W | 1 |
| Fisch, HU | 1 |
| Schlaepfer, TE | 1 |
| Cottone, P | 1 |
| Sabino, V | 1 |
| Steardo, L | 1 |
| Zorrilla, EP | 1 |
| Bouayed, J | 1 |
| Rammal, H | 1 |
| Dicko, A | 1 |
| Younos, C | 1 |
| Soulimani, R | 1 |
| Randall, PK | 1 |
| Bremner, JD | 1 |
| Krystal, JH | 2 |
| Nagy, LM | 1 |
| Heninger, GR | 2 |
| Nicolaou, AL | 1 |
| Charney, DS | 2 |
| Gorenstein, C | 1 |
| Bernik, MA | 1 |
| Pompéia, S | 1 |
| Uchiyama, M | 1 |
| Sue, H | 1 |
| Fukumitsu, N | 1 |
| Mori, Y | 1 |
| Kawakami, K | 1 |
| Takahashi, M | 1 |
| Odano, I | 1 |
| Fujita, S | 1 |
| Ohkubo, M | 1 |
| Nakabeppu, Y | 1 |
| Nakajo, M | 1 |
| Naruo, T | 1 |
| Obo, Y | 1 |
| Nozoe, S | 1 |
| Takigawa, M | 1 |
| Tsuchimochi, S | 1 |
| Tani, A | 1 |
| Tanaka, H | 1 |
| Krystal, AD | 1 |
| Watts, BV | 1 |
| Weiner, RD | 1 |
| Moore, S | 1 |
| Steffens, DC | 1 |
| Lindahl, V | 1 |
| Abadie, P | 1 |
| Boulenger, JP | 1 |
| Benali, K | 1 |
| Barré, L | 1 |
| Zarifian, E | 1 |
| Baron, JC | 1 |
| Cooper, MR | 1 |
| Malizia, AL | 1 |
| Giusti, P | 1 |
| Guidetti, G | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| Woods, SW | 1 |
| Silver, JM | 1 |
| Shanbhogue, R | 1 |
| Hrishikeshavan, HJ | 1 |
| Devi, K | 1 |
| Munonyedi, S | 1 |
| Nutt, DJ | 1 |
| Glue, P | 1 |
| Lawson, C | 1 |
| Wilson, S | 1 |
2 reviews available for flumazenil and Anxiety Neuroses
| Article | Year |
|---|---|
Benzodiazepines revisited--will we ever learn?
Topics: Accidents; Age Factors; Antidotes; Anxiety Disorders; Benzodiazepines; Cognition; Drug Prescriptions | 2011 |
What do brain imaging studies tell us about anxiety disorders?
Topics: Anxiety Disorders; Brain; Carbon Radioisotopes; Cerebrovascular Circulation; Flumazenil; Humans; Pan | 1999 |
7 trials available for flumazenil and Anxiety Neuroses
| Article | Year |
|---|---|
Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series.
Topics: Adult; Aged; Anxiety Disorders; Benzodiazepines; Female; Flumazenil; Humans; Infusions, Subcutaneous | 2013 |
Effects of the benzodiazepine antagonist flumazenil in PTSD.
Topics: Anxiety Disorders; Arousal; Combat Disorders; Double-Blind Method; Flumazenil; GABA Modulators; GABA | 1995 |
Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users.
Topics: Adult; Anxiety Disorders; Cognition; Depressive Disorder; Diazepam; Dose-Response Relationship, Drug | 1994 |
[Assessment of cerebral benzodiazepine receptor distribution in anxiety disorders by 123I-iomazenil-SPECT: comparison to cerebral perfusion scintigraphy by 123I-IMP].
Topics: Amphetamines; Anxiety Disorders; Brain; Cerebrovascular Circulation; Female; Flumazenil; Humans; Iod | 1997 |
Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study.
Topics: Adolescent; Adult; Anxiety Disorders; Carbon Radioisotopes; Female; Flumazenil; Humans; Male; Middle | 1999 |
Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder.
Topics: Adult; Aged; Analysis of Variance; Anxiety Disorders; Double-Blind Method; Female; Flumazenil; Human | 1991 |
Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Blood Pressure; Double-Blind Method; Female; Flumazenil; Heart | 1990 |
11 other studies available for flumazenil and Anxiety Neuroses
| Article | Year |
|---|---|
A theory of the anxiolytic action of flumazenil in anxiety disorders.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Flumazenil; gamma-Aminobutyric Acid; Humans; Hypoth | 2022 |
Intra-periaqueductal gray matter injections of midazolam fail to alter anxiety in plus-maze experienced mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Avoidance Learning; Disease Models, Animal | 2008 |
Diminished GABA(A) receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety.
Topics: Adult; Anxiety Disorders; Binding Sites; Brain Mapping; Cerebral Cortex; Depression; Electroconvulsi | 2004 |
FG 7142 specifically reduces meal size and the rate and regularity of sustained feeding in female rats: evidence that benzodiazepine inverse agonists reduce food palatability.
Topics: Animals; Anorexia; Anxiety Disorders; Appetite; Appetite Depressants; Appetite Regulation; Brain; Ca | 2007 |
Chlorogenic acid, a polyphenol from Prunus domestica (Mirabelle), with coupled anxiolytic and antioxidant effects.
Topics: Animals; Anti-Anxiety Agents; Antioxidants; Anxiety Disorders; Brain; Chlorogenic Acid; Exploratory | 2007 |
125I-iomazenil binding shows stress- and/or diazepam-induced reductions in mouse brain: supporting data for 123I-iomazenil SPECT study of anxiety disorders.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Autoradiography; Brain; Diazepam; Flumazenil; Iodin | 1997 |
I-123 iomazenil SPECT in patients with mental disorders.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Brain; Female; Flumazenil; Humans; Iodine Radioisotop | 1997 |
The use of flumazenil in the anxious and benzodiazepine-dependent ECT patient.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Depressive Disorder; Electroconvulsive | 1998 |
Re: I-123 iomazenil SPECT in patients with mental disorders.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Brain; Female; Flumazenil; Humans; Iodine Radioisotop | 1999 |
The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Ataxia; Behavior, Animal; Conflict, Psychological; | 1991 |
Behavioral neurobiology of inverse agonist FG 7142 induced anxiety syndrome in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Avoidance Learning; Carbolines; Diazepam; Explorato | 1990 |